
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street’s insatiable appetite for such treatments. Hopes of a soft landing for the U.S. economy and expectations of a more…